Correction: ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer.

IF 6.9 2区医学 Q1 ONCOLOGY

Molecular Cancer Therapeutics Pub Date : 2026-08-04 DOI:10.1158/1535-7163.MCT-26-0613

Isacco Ferrarini, Anna Louie, Lanlan Zhou, Wafik S El-Deiry

引用次数: 0

查看原文本刊更多论文

更正：ONC212是一种新型有丝分裂酶，可协同抑制胰腺癌的糖酵解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Cancer Therapeutics 医学-肿瘤学

CiteScore

11.20

自引率

1.80%

发文量

331

审稿时长

3 months

期刊介绍： Molecular Cancer Therapeutics will focus on basic research that has implications for cancer therapeutics in the following areas: Experimental Cancer Therapeutics, Identification of Molecular Targets, Targets for Chemoprevention, New Models, Cancer Chemistry and Drug Discovery, Molecular and Cellular Pharmacology, Molecular Classification of Tumors, and Bioinformatics and Computational Molecular Biology. The journal provides a publication forum for these emerging disciplines that is focused specifically on cancer research. Papers are stringently reviewed and only those that report results of novel, timely, and significant research and meet high standards of scientific merit will be accepted for publication.